Company Quick10K Filing
Pharmagreen Biotech
Price-0.00 EPS-0
Shares365 P/E0
MCap-0 P/FCF0
Net Debt-0 EBIT-1
TEV-0 TEV/EBIT0
TTM 2019-09-30, in MM, except price, ratios
10-Q 2020-06-30 Filed 2020-08-19
S-1 2020-05-08 Public Filing
10-Q 2020-03-31 Filed 2020-05-19
10-Q 2019-12-31 Filed 2020-02-18
10-Q 2019-06-30 Filed 2019-08-19
S-1 2019-03-20 Public Filing
8-K 2020-08-07 Bankruptcy, Off-BS Arrangement, Regulation FD, Other Events
8-K 2020-07-21 Enter Agreement
8-K 2020-05-22
8-K 2020-02-28
8-K 2020-01-23
8-K 2019-11-29
8-K 2019-11-08
8-K 2019-09-11

PHBI 10Q Quarterly Report

Part I - Financial Information2
Item 1. Financial Statements.2
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.188
Item 3. Quantitative and Qualitative Disclosures About Market Risk.21
Item 4. Controls and Procedures.211
Part II - Other Information23
Item 1. Legal Proceedings.232
Item 1A. Risk Factors.232
Item 2. Unregistered Sales of Securities and Use of Proceeds.232
Item 3. Defaults Upon Senior Securities.232
Item 4. Mine Safety Disclosure.232
Item 5. Other Information.232
Item 6. Exhibits.243
Part I - Financial Information
Item 1. Financial Statements.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures.
Part II - Other Information
Item 1. Legal Proceedings.
Item 1A. Risk Factors.
Item 2. Unregistered Sales of Securities and Use of Proceeds.
Item 3. Defaults Upon Senior Securities.
Item 4. Mine Safety Disclosure.
Item 5. Other Information.
Item 6. Exhibits.
EX-31.1 ex311.htm
EX-32.1 ex321.htm

Pharmagreen Biotech Earnings 2020-06-30

Balance SheetIncome StatementCash Flow

10-Q 1 10qpbi.htm PBI Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM  10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

or

[   ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

000-56090

Commission File Number

PHARMAGREEN BIOTECH INC.

(Exact name of registrant as specified in its charter)

Nevada  98-0491567 

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

2987 Blackbear Court, Coquitlam, British Columbia V3E 3A2 

(Address of principal executive offices)(Zip Code) 

702-803-9404

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 

(X)Yes (_) No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

(_)Yes (_) No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer

q

Non-accelerated filer

q

Accelerated filer

q

Smaller reporting company

x

 

 

Emerging Growth

x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act (X)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

(  ) Yes (X) No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

(  ) Yes (  ) No


 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of August 14, 2020, we had 95,806,289 shares of common stock issued and outstanding.


TABLE of CONTENTS

 

 

PART I—FINANCIAL INFORMATION2 

Item 1. Financial Statements.2 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.188 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.21 

Item 4.  Controls and Procedures.211 

PART II—OTHER INFORMATION23 

Item 1. Legal Proceedings.232 

Item 1A. Risk Factors.232 

Item 2. Unregistered Sales of Securities and Use of Proceeds.232 

Item 3. Defaults Upon Senior Securities.232 

Item 4. Mine Safety Disclosure.232 

Item 5. Other Information.232 

Item 6. Exhibits.243 

SIGNATURES254 


1


PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

 

PHARMAGREEN BIOTECH INC.

 

Condensed Consolidated Financial Statements

 

For the Nine Months Ended June 30, 2020

 

(Expressed in U.S. Dollars)

 

(unaudited)


2



PHARMAGREEN BIOTECH INC.

Condensed Consolidated Balance Sheets

(Expressed in U.S. dollars)

 

June 30,

2020

September 30,

2019

 

$

$

 

(unaudited)

 

Assets

 

 

 

 

 

Current assets

 

 

 

 

 

Cash

34,582

62,682

Amounts receivable

790

10,639

Prepaid expenses and deposits

352,654

115,856

 

 

 

Total current assets

388,026

189,177

 

 

 

Property and equipment (Note 3)

429,168

441,095

 

 

 

Total assets

817,194

630,272

 

 

 

Liabilities and Stockholders’ Deficit

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable and accrued liabilities (Notes 4 and 8)

558,699

855,766

Advances from Alliance Growers Corp. (Note 10(a))

55,103

56,634

Due to related parties (Note 8)

425,674

475,666

Loans payable (Note 5)

167,075

Convertible notes – current portion, net of unamortized discount of $459,006 and $2,895, respectively (Note 6)

57,894

75,105

Derivative liabilities (Note 7)

1,759,925

 

 

 

Total current liabilities

3,024,370

1,463,171

 

 

 

Loans payable (Note 5)

29,388

Convertible notes, net of unamortized discount of $24,632 and $27,321, respectively (Note 6)

2,888

1,599

 

 

 

Total liabilities

3,056,646

1,464,770

 

 

 

Stockholders’ deficit

 

 

 

 

 

Common stock

Authorized: 500,000,000 shares, $0.001 par value;

91,145,003 and 75,646,835 shares issued and outstanding, respectively

91,145

75,647

Additional paid-in capital

3,920,690

3,772,781

Accumulated other comprehensive income

49,869

47,824

Deficit

(6,299,721)

(4,729,476)

 

 

 

Total Pharmagreen Biotech Inc. stockholders’ deficit

(2,238,017)

(833,224)

 

 

 

Non-controlling interest

(1,435)

(1,274)

 

 

 

Total stockholders’ deficit

(2,239,452)

(834,498)

 

 

 

Total liabilities and stockholders’ deficit

817,194

630,272

 

 

 

Nature of business and continuance of operations (Note 1)

 

 

Commitments (Note 10)

 

 

Subsequent events (Note 11)

 

 


(The accompanying notes are an integral part of these condensed consolidated financial statements)

 

3



PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Expressed in U.S. dollars)

(unaudited)

 

Three months ended

June 30,

2020

$

Three months ended

June 30,

2019

$

Nine months ended

June 30,

2020

$

Nine months ended

June 30,

2019

$

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

 

Consulting fees (Note 8)

30,108

101,574

153,999

203,882

Foreign exchange loss (gain)

(15,824)

(45,387)

6,025

(10,192)

General and administrative

28,716

13,635

90,798

64,393

License application fees

(12)

1,545

890

3,470

Professional fees

40,068

15,052

89,915

78,417

Research and development

(32,655)

3,949

Salaries and wages

3,858

4,549

13,005

13,298

 

 

 

 

 

Total expenses

86,914

58,313

354,632

357,217

 

 

 

 

 

Net loss before other income (expenses)

(86,914)

(58,313)

(354,632)

(357,217)

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

Accretion of discount on convertible notes (Note 6)

(54,877)

(241)

(77,889)

(900)

Finance costs

(45,000)

(187,245)

Loss on change in fair value of derivative liabilities (Note 7)

(1,187,033)

(1,347,031)

Loss on settlement on convertible notes

(31,898)

(38,411)

Write-off of accounts payable (Note 4)

292,557

 

 

 

 

 

Total other income (expense)

(1,273,808)

(241)

(1,215,774)

(188,145)

 

 

 

 

 

Net loss before income taxes

(1,360,722)

(58,554)

(1,570,406)

(545,362)

 

 

 

 

 

Income tax recovery

802

802

 

 

 

 

 

Net loss

(1,360,722)

(57,752)

(1,570,406)

(544,560)

 

 

 

 

 

Less: net loss attributable to non-controlling interest

8

457

161

1,239

 

 

 

 

 

Net loss attributable to Pharmagreen Biotech Inc.

(1,360,714)

(57,295)

(1,570,245)

(543,321)

 

 

 

 

 

Comprehensive loss

 

 

 

 

 

 

 

 

 

Foreign currency translation gain (loss)

(17,081)

(49,722)

2,045

2,981

 

 

 

 

 

Comprehensive loss attributable to Pharmagreen Biotech Inc.

(1,377,795)

(107,017)

(1,568,200)

(540,340)

 

 

 

 

 

Basic and diluted loss per share attributable to Pharmagreen Biotech Inc. stockholders

(0.02)

(0.02)

(0.01)

 

 

 

 

 

Weighted average number of shares outstanding used in the calculation of net loss per share attributable to Pharmagreen Biotech Inc.  

82,854,083

74,671,845

78,042,762

73,714,096


(The accompanying notes are an integral part of these condensed consolidated financial statements)

 

4



PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Stockholders’ Deficit

(Expressed in U.S. dollars)

(unaudited)

 

 

Common stock

Additional paid-in capital

$

Accumulated

other

comprehensive income (loss)

$

Deficit

$

Non-controlling

interest

$

Total stockholders’

deficit

$

 

Number of shares

Amount

$

 

 

 

 

 

 

 

 

Balance, September 30, 2018

71,620,100

71,620

2,464,136

38,722

(3,961,939)

(1,387,461)

 

 

 

 

 

 

 

 

Issuance of common stock pursuant to conversion of convertible notes

2,000,000

2,000

(1,800)

200

 

 

 

 

 

 

 

 

Issuance of common stock for services

51,725

52

187,193

187,245

 

 

 

 

 

 

 

 

Foreign currency translation gain

98,770

98,770

 

 

 

 

 

 

 

 

Net loss for the period

(392,943)

(392,943)

 

 

 

 

 

 

 

 

Balance, December 31, 2018

73,671,825

73,672

2,649,529

137,492

(4,354,882)

(1,494,189)

 

 

 

 

 

 

 

 

Issuance of common stock pursuant to conversion of convertible notes

1,000,000

1,000

(900)

100

 

 

 

 

 

 

 

 

Issuance of common stock of 1155097 B.C. Ltd.

1,018,228

1,018,228

 

 

 

 

 

 

 

 

Foreign currency translation loss

(46,067)

(46,067)

 

 

 

 

 

 

 

 

Net loss for the period

(93,083)

(782)

(93,865)

 

 

 

 

 

 

 

 

Balance, March 31, 2019

74,671,825

74,672

3,666,857

91,425

(4,447,965)

(782)

(615,793)

 

 

 

 

 

 

 

 

Foreign currency translation loss

(49,722)

(49,722)

 

 

 

 

 

 

 

 

Net loss for the period

(57,295)

(457)

(57,752)

 

 

 

 

 

 

 

 

Balance, June 30, 2019

74,671,825

74,672

3,666,857

41,703

(4,505,260)

(1,239)

(723,267)


(The accompanying notes are an integral part of these condensed consolidated financial statements)

 

5



PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Stockholders’ Deficit (continued)

(Expressed in U.S. dollars)

(unaudited)

 

 

Common stock

Additional paid-in capital

$

Accumulated

other

comprehensive income (loss)

$

Deficit

$

Non-controlling

interest

$

Total stockholders’

deficit

$

 

Number of shares

Amount

$

 

 

 

 

 

 

 

 

Balance, September 30, 2019

75,646,835

75,647

3,772,781

47,824

(4,729,476)

(1,274)

(834,498)

 

 

 

 

 

 

 

 

Foreign currency translation loss

(12,399)

(12,399)

 

 

 

 

 

 

 

 

Net loss for the period

(206,021)

(36)

(206,057)

 

 

 

 

 

 

 

 

Balance, December 31, 2019

75,646,835

75,647

3,772,781

35,425

(4,935,497)

(1,310)

(1,052,954)

 

 

 

 

 

 

 

 

Issuance of common stock pursuant to the conversion of convertible notes

78,064

78

20,999

21,077

 

 

 

 

 

 

 

 

Foreign currency translation gain

31,525

31,525

 

 

 

 

 

 

 

 

Net loss for the period

(3,510)

(117)

(3,627)

 

 

 

 

 

 

 

 

Balance, March 31, 2020

75,724,899

75,725

3,793,780

66,950

(4,939,007)

(1,427)

(1,003,979)

 

 

 

 

 

 

 

 

Issuance of common stock pursuant to the conversion of convertible notes

15,420,104

15,420

126,910

142,330

 

 

 

 

 

 

 

 

Foreign currency translation loss

(17,081)

(17,081)

 

 

 

 

 

 

 

 

Net loss for the period

(1,360,714)

(8)

(1,360,722)

 

 

 

 

 

 

 

 

Balance, June 30, 2020

91,145,003

91,145

3,920,690

49,869

(6,299,721)

(1,435)

(2,239,452)


(The accompanying notes are an integral part of these condensed consolidated financial statements)

 

6



PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Cash Flows

(Expressed in U.S. dollars)

(unaudited)

 

Nine months

ended

June 30,

2020

Nine months

ended

June 30,

2019

 

$

$

 

 

 

OPERATING ACTIVITIES

 

 

 

 

 

Net loss

(1,570,406)

(544,560)

 

 

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Accretion of discount on convertible notes

77,889

900

Financing fees

45,000

Loss on change in fair value of derivative liabilities

1,347,031

Loss on settlement of convertible note

38,411

Shares issued for services

187,245

Write-off of accounts payable

(292,557)

 

 

 

Changes in non-cash operating assets and liabilities:

 

 

Accounts receivable and other receivables

9,849

18,502

Prepaid expenses and deposits

(236,798)

(7,314)

Accounts payable and accrued liabilities

21,189

225,447

Due to related parties

13,840

22,596

 

 

 

Net cash used in operating activities

(546,552)

(97,184)

 

 

 

INVESTING ACTIVITIES

 

 

 

 

 

Acquisition of property and equipment

(281,454)

 

 

 

Net cash used in investing activities

(281,454)

 

 

 

FINANCING ACTIVITIES

 

 

 

 

 

Proceeds from issuance of convertible notes

570,080

Proceeds from advances from Alliance Growers Corp.

170,032

Proceeds from loans from related parties

64,981

206,331

Repayment of loans from related parties

(128,813)

(101,612)

Proceeds from loans payable

29,388

Financing costs

(5,000)

 

 

 

Net cash provided by financing activities

530,636

274,751

 

 

 

Effect of foreign exchange rate changes on cash

(12,184)

(35,093)

 

 

 

Change in cash

(28,100)

(138,980)

 

 

 

Cash, beginning of period

62,682

151,869

 

 

 

Cash, end of period

34,582

12,889

 

 

 

Non-cash investing and financing activities:

 

 

 

 

 

Original issue discount on convertible notes

532,594

Issuance of common stock pursuant to conversion of convertible notes

163,407

300

Issuance of equity in 1155097 B.C. Ltd in exchange for advances payable

1,018,229

Issuance of promissory note as a financing fee

40,000

 

 

 

Supplemental disclosures:

 

 

 

 

 

Interest paid

4,601

Income taxes paid


(The accompanying notes are an integral part of these condensed consolidated financial statements)

 

7


PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2020

(Expressed in U.S. dollars)

(unaudited)


1.Nature of Business and Continuance of Operations 

Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of the State of Nevada, U.S. on November 26, 2007, under the name Azure International, Inc.  On October 30, 2008, and effective as of the same date, the Company filed Articles of Merger (“Articles”) with the Secretary of State of the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation and Azure International, Inc.  As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc.  The Company was previously in the business of providing technical advisory and appraisals to the aircraft and aviation business as well as providing sourcing for aircraft leases and parts. Pursuant to a Share Exchange Agreement with WFS Pharmagreen Inc. (“WFS”) on May 2, 2018, the Company changed its name to Pharmagreen Biotech Inc. and changed its principal business to the construction of a biotech complex in Deroche, British Columbia, Canada, for the purpose of producing a variety of starter plantlets for the Canadian and international high CBD hemp and medical cannabis industries through the application of the proprietary plant tissue culture in vitro process called “Chibafreen”. This proprietary process will produce plantlets that will be genetically identical and free of pests and disease free with consistent and certifiable constituent properties.

Going Concern

These condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at June 30, 2020, the Company has not earned any revenues from operations, has a working capital deficit of $2,636,344, and has an accumulated deficit of $6,299,721. During the nine months ended June 30, 2020, the Company incurred a net loss of $1,570,406 and used cash flows for operations of $546,552.  In addition, the Company filed voluntary petitions for reorganization under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada on August 7, 2020. Refer to Note 11.  These factors raise substantial doubt upon the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.   

The recent outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies, disruptions of financial markets, and created uncertainty regarding potential impacts to the Company’s supply chain, operations, and customer demand. The COVID-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s suppliers and vendors as a result of quarantines, facility closures, and travel and logistics restrictions. The extent to which the COVID-19 pandemic impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local and federal governments, and to what extent normal economic and operating conditions can resume. The management team is closely following the progression of COVID-19 and its potential impact on the Company.  Even after the COVID-19 pandemic has subsided, the Company may experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time our business, liquidity, capital resources and financial results.

2.Significant Accounting Policies 

(a)Interim Financial Statements 

These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

(b)Basis of Presentation  

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 BC Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.


8


PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2020

(Expressed in U.S. dollars)

(unaudited)


2.Significant Accounting Policies (continued) 

(c)Use of Estimates and Judgments  

The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the allowance for doubtful accounts, the recoverability of property and equipment, the equity component of convertible notes, fair value of derivative liabilities, fair value of stock-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

(d)Loss Per Share 

The Company computes loss per share in accordance with ASC 260, "Earnings per Share" which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing the loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As at June 30, 2020, there were 386,438,931 (September 30, 2019 – 364,850,535) potentially dilutive shares outstanding.

(e)  Recently Adopted Accounting Pronouncements

In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The standard became effective for the Company in the first quarter of fiscal year 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

In February 2016, Topic 842, Leases, was issued to replace the leases requirements in Topic 840, Leases. The main difference between previous GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. The standard became effective for the Company in the first quarter of fiscal year 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.  

The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.


9


PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2020

(Expressed in U.S. dollars)

(unaudited)


3.Property and Equipment 

 

 

 

 

Construction in progress

$

 

 

 

 

 

Cost

 

 

 

 

 

 

 

 

 

Balance, September 30, 2019

 

 

 

441,095

 

 

 

 

 

Change due to foreign exchange

 

 

 

(11,927)

 

 

 

 

 

Balance, June 30, 2020

 

 

 

429,168

As at June 30, 2020, and September 30, 2019, costs related to the construction of cannabis production complex were capitalized as construction in progress and not depreciated. Depreciation will commence when construction is completed, and the facility is available for its intended use.

 

4.Accounts Payable and Accrued Liabilities  

Accounts payable and accrued liabilities consists of the following:

 

June 30,

2020

$

September 30,

2019

$

 

 

 

Accounts payable

505,138

829,942

Accrued interest payable

53,561

25,824

 

 

 

 

558,699

855,766

During the nine months ended June 30, 2020, the Company recognized a write-off of accounts payable of $292,557 (2019 - $nil) related to professional fees that are no longer owing.

 

5.Loans Payable 

On November 22, 2019, the Company entered into a promissory note with an unrelated party for $40,000 in connection with an equity purchase agreement (Refer to Note 10(b)). The promissory note is unsecured, due on November 30, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum. During the nine months ended June 30, 2020, the Company recognized accrued interest of $2,415 (2019 - $nil).

On April 22, 2020, the Company received a loan for $29,388 (Cdn$40,000) from the Government of Canada under the Canada Emergency Business Account program (“CEBA”). These funds are interest free until December 31, 2022, at which time the remaining balance will convert to a 3-year term loan at an interest rate of 5% per annum. If the Company repays the loan prior to December 31, 2022, there will be loan forgiveness of 25%, up to Cdn$10,000.

On June 17, 2020, the Company entered into a settlement agreement with a convertible note holder, wherein the Company and the lender agreed to settle 3 convertible notes and accrued interest (Notes 6(b), (d) and (e)) for a total of $141,676 on a non-convertible basis, of which $14,601 is payable on or before June 24, 2020 (paid), $68,775 is payable on or before September 30, 2020, and the remaining $58,300 is payable on or before January 6, 2021.


10


PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2020

(Expressed in U.S. dollars)

(unaudited)


6.Convertible Notes  

(a)On April 4, 2018, the amount of $32,485 owed to related parties was converted to Series A convertible notes, which are unsecured, non-interest bearing, and due on April 4, 2023. These notes are convertible in whole or in part, at any time until maturity, to common shares of the Company at $0.0001 per share. The outstanding balance remaining at maturity shall bear interest at 12% per annum until fully paid. The Company evaluated the convertible notes for a beneficial conversion feature in accordance with ASC 470-20 Debt with Conversion and Other Options. The Company determined that the conversion price was below the closing stock price on the commitment date, and the convertible notes contained a beneficial conversion feature. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $32,485 as additional paid-in capital and reduced the carrying value of the convertible note to $nil. The carrying value will be accreted over the term of the convertible notes up to their face value of $32,485.  

During the year ended September 30, 2018, the Company issued 31,745,000 shares of common stock upon the conversion of $3,175 of Series A convertible notes, which included 18,000,000 common shares to the President of the Company and 5,320,000 common shares to family members of the President of the Company. Upon conversion, the Company immediately recognized the related remaining debt discount of $3,112 as accretion expense.

During the year ended September 30, 2019, the Company issued 3,900,000 shares of common stock upon the conversion of $390 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $375 as accretion expense.

During the nine months ended June 30, 2020, the Company issued 14,000,000 shares of common stock upon the conversion of $1,400 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $1,331 as accretion expense.

As at June 30, 2020, the carrying value of the convertible notes was $2,888 (September 30, 2019 – $1,599) and had an unamortized discount of $24,632 (September 30, 2019 - $27,321). During the nine months ended June 30, 2020, the Company recorded accretion expense of $1,358 (2019 - $900).

(b)On September 17, 2019, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,000 was paid directly to third parties for financing costs, resulting in cash proceeds to the Company of $75,000. The note is due on September 20, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. Due to this provision, the Company considered whether the embedded conversion option qualifies for derivative accounting under ASC 815-15 Derivatives and Hedging. As the note was not convertible until 180 days following issuance, no derivative liability was initially recognized. 

The convertible note became convertible on March 15, 2020. The Company evaluated the convertible note for a beneficial conversion feature in accordance with ASC 470-20 Debt with Conversion and Other Options. The Company determined that the conversion price was below the closing stock price on the measurement date, and the convertible note contained a beneficial conversion feature. The initial fair value of the conversion feature was determined to be $82,631. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $76,019 and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $75,000.

During the nine months ended June 30, 2020, the Company issued 1,498,168 shares of common stock upon the conversion of $68,000 of the convertible note. Upon conversion, the Company immediately recognized the related remaining debt discount of $64,104 as accretion expense.

On June 17, 2020, the Company entered into a Settlement Agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal of $10,000 and accrued interest owing on the note (Note 5). Upon entering into the Settlement Agreement, the remaining balance owing was transferred to loans payable on the balance sheet, and the Company immediately recognized the remaining debt discount of $4,427.

The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the nine months ended June 30, 2020, the Company recognized accretion expense of $10,487 (2019 - $nil). As at June 30, 2020, the carrying value of the convertible note was $nil (September 30, 2019 - $75,105), net of an unamortized discount of $nil (September 30, 2019 - $2,895).


11


PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2020

(Expressed in U.S. dollars)

(unaudited)


6.    Convertible Notes (continued)

(c)On October 1, 2019, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,255 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $74,745. The note is due on October 1, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period prior to the issuance date; or (ii) 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $70,744. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,245 and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000. 

The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the nine months ended June 30, 2020, the Company recognized accretion expense of $30,596. As at June 30, 2020, the carrying value of the convertible note was $31,096, net of an unamortized discount of $46,904. Refer to Note 11(b).

(d)On October 17, 2019, the Company entered into a convertible note with an unrelated party for $63,000, of which $3,000 was paid directly to third parties for financing costs, resulting in cash proceeds to the Company of $60,000. The note is due on October 17, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. In December 2019, the conversion price was amended to 46%. Due to this provision, the Company considered whether the embedded conversion option qualifies for derivative accounting under ASC 815-15 Derivatives and Hedging. As the note isn’t convertible until 180 days following issuance, no derivative liability was recognized as of June 30, 2020. 

On June 17, 2020, the Company entered into a settlement agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal of $63,000 and accrued interest owing on the note (Note 5). Upon entering into the Settlement Agreement, the remaining balance owing was transferred to loan payable on the balance sheet, and the Company immediately recognized the remaining debt discount of $1,657.

The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the nine months ended June 30, 2020, the Company recognized accretion expense of $1,343. As at June 30, 2020, the carrying value of the convertible note was $nil.

(e)On January 2, 2020, the Company entered into a convertible note with an unrelated party for $53,000, of which $3,000 was paid directly to third parties for financing costs, resulting in cash proceeds to the Company of $50,000. The note is due on January 2, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. Due to this provision, the Company considered whether the embedded conversion option qualifies for derivative accounting under ASC 815-15 Derivatives and Hedging. As the note isn’t convertible until 180 days following issuance, no derivative liability was recognized as of June 30, 2020. 


12


PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2020

(Expressed in U.S. dollars)

(unaudited)


6.    Convertible Notes (continued)

On June 17, 2020, the Company entered into a Settlement Agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal of $53,000 and accrued interest owing on the note (Note 5). Upon entering into the Settlement Agreement, the remaining balance owing was transferred to loan payable on the balance sheet, and the Company immediately recognized the remaining debt discount of $2,286.

The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the nine months ended June 30, 2020, the Company recognized accretion expense of $714. As at June 30, 2020, the carrying value of the convertible note was $nil.

(f)On January 14, 2020, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,000 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $75,000. The note is due on January 14, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 15% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) 65% of the lowest trading price during the 20-trading day period prior to the issuance date; or (ii) 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $76,330. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,500, resulting in a loss on change in fair value of derivative liabilities of $1,830, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000. 

The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the nine months ended June 30, 2020, the Company recognized accretion expense of $4,515. As at June 30, 2020, the carrying value of the convertible note was $5,015, net of an unamortized discount of $72,985.

(g)On January 15, 2020, the Company entered into a convertible note with an unrelated party for $61,000, of which $7,400 was paid directly to third parties for financing costs. The convertible note has a purchase price of $58,000, with an original issue discount of $3,000, resulting in proceeds to the Company of $50,600. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $67,846. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $50,100, resulting in a loss on change in fair value of derivative liabilities of $17,746, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $61,000. 

The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the nine months ended June 30, 2020, the Company recognized accretion expense of $3,934. As at June 30, 2020, the carrying value of the convertible note was $4,434, net of an unamortized discount of $56,566.

Subsequent to June 30, 2020, the Company entered into a settlement agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal of $61,000 and accrued interest owing on the note (Note 11(c)).


13


PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2020

(Expressed in U.S. dollars)

(unaudited)


6.Convertible Notes (continued) 

(h)On January 15, 2020, the Company entered into a convertible note with an unrelated party for $55,000, of which $2,500 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $52,500. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 65% of the lowest trading price during the 20 consecutive trading day period on which at least 100 shares of common stock were traded prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $61,173. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $52,000, resulting in a loss on change in fair value of derivative liabilities of $9,173, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $55,000. 

The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the nine months ended June 30, 2020, the Company recognized accretion expense of $3,733. As at June 30, 2020, the carrying value of the convertible note was $4,232, net of an unamortized discount of $50,768.

(i)On January 21, 2020, the Company entered into a convertible note with an unrelated party for $66,150, of which $7,800 was paid directly to third parties for financing costs. The convertible note has a purchase price of $63,000, with an original issue discount of $3,150, resulting in proceeds to the Company of $55,200. The note is due on January 21, 2021, and bears interest on the unpaid principal balance at a rate of 8% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 60% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $71,278. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $54,700, resulting in a loss on change in fair value of derivative liabilities of $16,578, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $66,150. 

The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the nine months ended June 30, 2020, the Company recognized accretion expense of $3,770. As at June 30, 2020, the carrying value of the convertible note was $4,270, net of an unamortized discount of $61,880.

(j)On January 22, 2020, the Company entered into a convertible note with an unrelated party for $78,750, of which $9,750 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $69,000. The note is due on January 22, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $75,179. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $68,500, resulting in a loss on change in fair value of derivative liabilities of $6,679, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,750. 


14


PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2020

(Expressed in U.S. dollars)

(unaudited)


6.    Convertible Notes (continued)

The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the nine months ended June 30, 2020, the Company recognized accretion expense of $4,049. As at June 30, 2020, the carrying value of the convertible note was $4,549, net of an unamortized discount of $74,201.

(k)On February 4, 2020, the Company entered into a convertible note with an unrelated party for $100,000, of which $16,970 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $83,030. The note is due on February 4, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 60% of the average of the two lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $125,640. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $82,530, resulting in a loss on change in fair value of derivative liabilities of $43,110, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $100,000. 

The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the nine months ended June 30, 2020, the Company recognized accretion expense of $3,798. As at June 30, 2020, the carrying value of the convertible note was $4,298, net of an unamortized discount of $95,702.

 

7.Derivative Liabilities 

The embedded conversion option of the Company’s convertible notes described in Note 6 contain a conversion feature that qualifies for embedded derivative classification.  The fair value of this liability will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement of operations as a gain or loss on change in fair value of derivative liabilities. The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities:

 

 

Balance

$

 

 

 

Balance, September 30, 2019

 

 

 

 

Addition of new derivative liabilities

 

645,319

Conversion of convertible notes

 

(119,700)

Change in fair value of embedded conversion option

 

1,234,306

 

 

 

Balance, June 30, 2020

 

1,759,925

The Company uses Level 3 inputs for its valuation methodology for the embedded conversion option liabilities as their fair values were determined by using a binomial model based on various assumptions. Significant changes in any of these inputs in isolation would result in a significant change in the fair value measurement. As required, these are classified based on the lowest level of input that is significant to the fair value measurement. The following table shows the assumptions used in the calculations:

 

Expected

volatility

Risk-free interest rate

Expected dividend yield

Expected life (in years)

 

 

 

 

 

As at date of issuance

123.84% to 192.74%

0.38% to 1.73%

0%

0.51 to 1.00

As at June 30, 2020

239.46% to 283.70%

0.16% to 0.18%

0%

0.25 to 0.59


15


PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2020

(Expressed in U.S. dollars)

(unaudited)


8.Related Party Transactions 

(a)As at June 30, 2020, the Company owed $356,980 (Cdn$485,885) (September 30, 2019 - $372,799 (Cdn$493,694)) to the President of the Company, which is non-interest bearing, unsecured, and due on demand. During the nine months ended June 30, 2020, the Company incurred consulting fees of $63,044 (2019 - $67,700) to the President of the Company. 

(b)As at June 30, 2020, the Company owed $14,694 (Cdn$20,000) (September 30, 2019 - $47,367 (Cdn$62,730)) to a company controlled by the President of the Company, which is non-interest bearing, unsecured, and due on demand. 

(c)As at June 30, 2020, the Company owed $54,000 (Cdn$73,500) (September 30, 2019 - $55,500 (Cdn$73,500)) to the father of the President of the Company, which is non-interest bearing, unsecured, and due on demand.  

(d)As at June 30, 2020, the Company owed $25,127 (Cdn$34,200) (September 30, 2019 - $25,825 (Cdn$34,200)) to a Company owned by the father of the President of the Company, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand.  

(e)As at June 30, 2020, the Company owed $314,560 (Cdn$428,148) (September 30, 2019 – $291,504 (Cdn$386,039)) to a company controlled by the Chief Financial Officer of WFS, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. During the nine months ended June 30, 2020, the Company incurred consulting fees of $63,044 (2019 - $67,700) to the company controlled by the Chief Financial Officer of WFS. 

9.Common Stock 

(a)On March 24, 2020, the Company issued 78,064 shares of common stock with a fair value of $21,077 pursuant to the conversion of $10,000 of a convertible note (Note 6(b)). 

(b)On April 1, 2020, the Company issued 6,000,000 shares of common stock pursuant to the conversion of $600 of a convertible note (Note 6(a)). 

(c)On April 2, 2020, the Company issued 136,612 shares of common stock pursuant to the conversion of $10,000 of a convertible note (Note 6(b)). 

(d)On April 16, 2020, the Company issued 351,288 shares of common stock pursuant to the conversion of $15,000 of a convertible note (Note 6(b)). 

(e)On April 30, 2020, the Company issued 423,729 shares of common stock pursuant to the conversion of $15,000 of a convertible note (Note 6(b)). 

(f)On May 4, 2020, the Company issued 508,475 shares of common stock pursuant to the conversion of $18,000 of a convertible note (Note 6(b)). 

(g)On June 30, 2020, the Company issued 8,000,000 shares of common stock pursuant to the conversion of $800 of a convertible note (Note 6(a)). 

10.Commitments  

(a)Effective December 11, 2017, the Company entered into a binding Letter of Intent (“LOI”) with Alliance Growers Corp. (“Alliance”), whereby the Company will build a new cannabis biotech complex located in Deroche, British Columbia, through their subsidiary, 115BC. On January 25, 2019, the Company’s wholly owned subsidiaries WFS and 115BC entered into an option agreement with Alliance, which superseded the LOI entered into on December 11, 2017. The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000. On January 25, 2019, 115BC issued 8 shares of common stock to Alliance upon exercise of the first option for consideration of $1,018,182 (Cdn$1,350,008), which was recognized as additional paid-in capital. The second option expired unexercised. As at June 30, 2020, the Company received advances of $55,103 (Cdn$75,000) (September 30, 2019 - $56,634 (Cdn$75,000)) from Alliance, which is unsecured, non-interest bearing, and due on demand. 


16


PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2020

(Expressed in U.S. dollars)

(unaudited)


10.Commitments (continued) 

(b)On November 22, 2019, the Company entered into an equity purchase agreement with an unrelated party, whereby the third party is to purchase up to $10,000,000 of the Company’s common stock. The equity purchase agreement is effective for a term of 2 years from the effective date of the registration statement. The purchase price would be 85% of the market price. In return, the Company issued a promissory note of $40,000 (Refer to Note 5). In addition, the third party is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing.  

11.Subsequent Events 

(a)On July 9, 2020, the Company entered into a consulting agreement for management consulting and strategic business advisory services for a term of 30 days. In consideration, the Company issued 22,000 restricted shares of common stock. 

(b)On July 22, 2020, the Company received a preliminary statement of claim from a convertible note holder for failure of the Company to deliver shares of common stock upon receipt of notices of conversion. Pursuant to the claim, the plaintiff has requested receipt of all shares of common stock requested in the notices of conversion, and also damages in an amount to be determined at trial but in any event in excess of principal in the sum of $180,000, including without limitation the balance of any portion of the convertible note that ultimately is not converted into shares of common stock, along with default interest, liquidated damages, and damages as provided for in the convertible note. Refer to Note 6(c). 

(c)On July 23, 2020, the Company entered into a Settlement Agreement with a convertible note holder, wherein the Company and the lender agreed to settle a convertible note and accrued interest (Note 6(g)) for a total of $63,440 on a non-convertible basis, of which $15,000 is payable on or before July 24, 2020 (paid), followed by 6 monthly installment payments of $8,073. 

(d)On July 31, 2020, the Company issued a total of 4,525,000 shares of common stock pursuant to the conversions of an aggregate of $453 of a convertible note. 

(e)On July 31, 2020, the Company issued 114,286 shares of common stock at $0.35 per share for proceeds of $40,000. 

(f)On August 7, 2020, (the “Petition Date”), the Company filed voluntary petitions for reorganization (the “Bankruptcy Petitions” and the cases commenced thereby, the “Chapter 11 Cases”) under chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Nevada (the “Court”). The Company’s filing with the Court was designated as Case No. 20-13886. During the pendency of this matter, the Company has also filed motions with the Court seeking authorization to continue to operate its businesses as “debtors-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. The Company expects to continue its existing operations without interruption during the pendency of the Chapter 11 Cases. To maintain and continue uninterrupted ordinary course operations during the Chapter 11 Cases, the Company has filed a variety of “first day” motions seeking approval from the Court for various forms of customary relief. These motions are designed primarily to minimize the effect of bankruptcy on the Company’s operations, customers, and employees. 


17



Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward-Looking Statements

 

This section of the Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

 

Company History Overview

 

Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of Nevada, U.S. on November 26, 2007 under the name Azure International, Inc. On October 30, 2008 and effective as of the same date, the Company filed Articles of Merger with the Secretary of the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation incorporated on October 16, 2008, and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc.

 

Air Transport Group Holdings, Inc. was originally set up to be in the business of acquiring aviation, travel and leisure companies.  During February 2018, change of control of the Company was effected and on February 21, 2018 new management took over.

 

On April 12, 2018, the Company entered into a share exchange agreement with WFS Pharmagreen Inc., a private company incorporated under the laws of British Columbia, Canada, whereby the Company acquired all of the issued and outstanding shares of WFS Pharmagreen Inc. in exchange for 37,704,500 shares of common stock of the Company. Upon completion of this transaction, the shareholders of WFS Pharmagreen hold 95.5% of voting control of the Company.

 

Immediately prior to closing of the Agreement, the majority shareholder of the Company was also the majority shareholder of WFS. As a result of the common ownership upon closing of the transaction, the acquisition was considered a common-control transaction and was outside the scope of the business combination guidance in ASC 805-50. The entities are deemed to be under common control as of February 27, 2018, which was the date that the majority shareholder acquired control of the Company and, therefore, held control over both companies. On May 2, 2018, the Share Exchange Agreement was effected. In connection with this transaction, the Company changed its name on May 8, 2018 to Pharmagreen Biotech Inc. and changed its year end from April 30th to September 30th.

 

Our principal executive offices are temporarily located at 2987 Blackbear Court, Coquitlam, British Columbia, Canada. Our telephone number is (702-803-9404). Our internet address is www.pharmagreen.ca.

 

On August 7, 2020, (the “Petition Date”), the Company filed voluntary petitions for reorganization (the “Bankruptcy Petitions” and the cases commenced thereby, the “Chapter 11 Cases”) under chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Nevada (the “Court”). The Company’s filing with the Court was designated as Case No. 20-13886. During the pendency of this matter, the Company has also filed motions with the Court seeking authorization to continue to operate its businesses as “debtors-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. The Company expects to continue its existing operations without interruption during the pendency of the Chapter 11 Cases. To maintain and continue uninterrupted ordinary course operations during the Chapter 11 Cases, the Company has filed a variety of “first day” motions seeking approval from the Court for various forms of customary relief. These motions are designed primarily to minimize the effect of bankruptcy on the Company’s operations, customers and employees.

 

We expect to continue to incur losses for at least the next 12 months. We do not expect to generate revenue that is sufficient to cover our expenses, and we do not have sufficient cash and cash equivalents to execute our plan of operations for at least the next twelve months. We will need to obtain additional financing, through equity security sales, debt instruments and private financing, to conduct our day-to-day operations, and to fully execute


18



our business plan. We plan to raise the capital necessary to fund our business through the sale of equity securities, debt instruments or private financing.

 

Our Current Business

 

The Company was incorporated under the laws of the State of Nevada on November 26, 2007. The Company is headquartered in Coquitlam, British Columbia.  The Company’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of high CBD hemp and other flora and offering full spectrum DNA testing for plant identification, live genetics preservation using  low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American high CBD hemp, Cannabis and agriculture sectors.

 

Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. However, if the Company is unable to raise additional capital in the near future, due to the Company’s liquidity problems, management expects that the Company will need to curtail operations, liquidate assets, seek additional capital on less favorable terms and/or pursue other remedial measures. The condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Its immediate focus will be on producing tissue cultured high CBD hemp starter plantlets.  In the early part of 2018, the Company’s wholly owned Canadian subsidiary, WFS Pharmagreen Inc., applied to Health Canada for a license to produce and sell tissue culture plantlets and cannabis oil.  On February 7, 2019, The Company’s, wholly owned Canadian subsidiary, WFS Pharmagreen Inc., received notification from Health Canada that its cannabis licensing application under the Cannabis Act and the Cannabis Regulations to obtain a license at the proposed site in Deroche, British Columbia, Canada has advanced from the first stage, “Intake and Screening” to the second stage, “Detailed Review and Initiation of Security Clearance Process,” of a three stage approval process. On May 10, 2019, the Company received confirmation from Health Canada that the second stage review was completed and that the Company can proceed to the third and final stage, construction of the biotech complex for final inspection and licensing.

 

Detailed Review and Initiation of Security Clearance Process means applications are reviewed against the licensing and personnel security requirements of the regulations.

 

The third stage is Confirmation of Readiness: Confirmation is provided to the applicant that the application substantively meets the requirements and asks for confirmation that the site is ready for licensing or inspection. This stage will be dependent on the timing of completing the development of its site.in Deroche, British Columbia Canada. The Company does not anticipate any additional costs related to this stage.

 

The Company is currently completing its engineering stage and has begun site development work for the building process of a 63,000 square foot biotech complex.

 

On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. The impact on the Company is not currently determinable, but management continues to monitor the situation.

 

Capital Resources and Liquidity

 

Our auditors have issued a “going concern” opinion for our year ended September 30, 2019, meaning that there is substantial doubt if we can continue as an on-going business unless we obtain additional capital. No substantial revenues from our planned business model are anticipated until we have completed financing the Company. As at June 30, 2020, the Company has a working capital deficit of $2,636,344 and an accumulated deficit of $6,299,721. In addition, as mentioned above, the Company filed voluntary petitions for reorganization under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada on August 7, 2020. These factors raise substantial doubt about the Company’s ability to continue as a going concern.


19



We need to seek capital from resources such as the sale of private placements in the Company’s common stock or debt financing, which may not even be available to the Company. However, if such financing were available, because we are an early stage company with no or limited operations to date, it would likely have to pay additional costs associated with such financing and in the case of high risk loans be subject to an above market interest rate. At such time these funds are required, management would evaluate the terms of such financing. If the company cannot raise additional proceeds via such financing, it may be required to cease business operations.

 

As of June 30, 2020, we had $34,582 in cash, accounts receivable and other receivables of $790 and prepaid expenses and deposits of $352,654 as compared to $62,682 in cash, accounts receivable and other receivables of $10,639 and prepaid expenses and deposits of $115,856 as of September 30, 2019.  Overall, our cash position is lower and our prepaid expenses and deposits are higher as we have spent more funding on the planned build-out of our biotech complex, of which $102,654 was prepaid as at June 30, 2020. Prepaid expenses and deposits also include deferred financing costs of $250,000 associated with the Company’s plan to issue an Exchange Traded Note on the Vienna Stock Exchange. As of the date of this Form 10-Q, the current funds available to the Company will not be sufficient to fund the expenses related to maintaining our planned operations. We are in the process of seeking additional equity financing in the form of private placements, loans and registration statements to fund our intended business operations.

 

Management believes that if subsequent private placements are successful or we are successful in raising funds from registered securities, we will generate sales revenue within twelve months thereof. However, additional equity financing may not be available to us on acceptable terms or at all, and thus we could fail to satisfy our future cash requirements.


We do not anticipate researching any further products nor the purchase or sale of any significant equipment. We also do not expect any significant additions to the number of employees.

 

Results of Operations

 

Three Months Ended June 30, 2020

 

We had $nil in revenue for the three months ended June 30, 2020 and 2019.  

 

Total expenses in the three months ended June 30, 2020 were $86,914 as compared to total expenses for the three months ended June 30, 2019 of $58,313. The net increase in expenses during the current period is mainly due to a change in foreign exchange gain from $45,387 in 2019 to $15,824 in 2020, due to fluctuations in the Canadian dollar exchange rate and changes in the Company’s Canadian dollar assets and liabilities, a recovery of research and development costs of $32,655 in 2019 compared to $nil in 2020, and an increase in professional fees from $15,052 in 2019 to $40,068 in 2020, which were higher due to indirect costs associated with the issuance of convertible notes during the period. The increase in overall expenses during the three months ended June 30, 2020 was reduced by the decrease in consulting fees from $101,574 in 2019 to $30,108 in 2020.  

 

We incurred a comprehensive loss of $1,377,795 during the three months ended June 30, 2020, compared to a comprehensive loss of $107,017 during the three months ended June 30, 2019.  The increase in comprehensive income was mainly attributable to a loss on change in fair value of derivative liability of $1,187,033 related to the Company’s convertible notes.

 

During the three months ended June 30, 2020, and 2019, we incurred a net loss of $0.02 and $0.00 per share, respectively.

 

Nine Months Ended June 30, 2020

 

We had $nil in revenue for the nine months ended June 30, 2020 and 2019.  

 

Total expenses in the nine months ended June 30, 2020 were $354,632 which was comparable to the total expenses for the nine months ended June 30, 2019 of $357,217.

 

We incurred a comprehensive loss of $1,568,200 during the nine months ended June 30, 2020, compared to a comprehensive loss of $540,340 during the nine months ended June 30, 2019.  In addition to operating expenses, we incurred finance costs of $45,000 relating to commitment fees paid pursuant to an Equity Purchase


20



Agreement dated November 22, 2019, with Oscaleta Partners LLC. The term of the Equity Purchase Agreement is for a period that expires 2 years after the effective date of the related registration statement. The Company also incurred accretion expenses of $77,889 and a loss on change in fair value of derivative liability of $1,347,031 related to the Company’s convertible notes, offset by a gain on write-off of accounts payable of $292,557 relating to professional fees that are no longer outstanding. For the nine months ended June 30, 2019, the Company incurred finance costs of $187,245 relating to the fair value of common stock issued as commitment fees related to an Equity Purchase Agreement entered into on November 9, 2018, with L2 Capital LLC.

 

During the nine months ended June 30, 2020, and 2019, we incurred a net loss of $0.02 and $0.01 per share, respectively.

 

 

Off-balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the company is a party, under which the company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

 

 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 4.  Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

 

In connection with this quarterly report, as required by Rule 15d-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of the design and operation of our company's disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our company's management, including our company's principal executive officer and principal financial officer. Based upon that evaluation, our company's principal executive officer and principal financial officer concluded that as of June 30, 2020 our disclosure controls and procedures were not effective due to the existence of material weaknesses in our internal controls over financial reporting.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f)) during the quarter ended June 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

Saturna Group Chartered Professional Accountants LLP, our independent auditors, are not required to and have not performed an assessment of our internal controls over financial reporting.


21



PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

On July 22, 2020, the Company received a preliminary statement of claim from a convertible note holder for failure of the Company to deliver shares of common stock upon receipt of notices of conversion. Pursuant to the claim, the plaintiff has requested receipt of all shares of common stock requested in the notices of conversion, and also damages in an amount to be determined at trial but in any event in excess of principal in the sum of $180,000, including without limitation the balance of any portion of the convertible note that ultimately is not converted into shares of common stock, along with default interest, liquidated damages, and damages as provided for in the convertible note.

 

Also, as mentioned above, the Company filed voluntary petitions for reorganization under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada on August 7, 2020. The Company’s filing with the Court was designated as Case No. 20-13886. During the pendency of this matter, the Company has also filed motions with the Court seeking authorization to continue to operate its businesses as “debtors-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. 

Item 1A. Risk Factors.

 

As a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

Item 2. Unregistered Sales of Securities and Use of Proceeds.

 

None

Item 3. Defaults Upon Senior Securities.

 

The commencement of the Chapter 11 Cases discussed above constitutes an event of default under certain of the Company’s debt instruments, including various convertible notes, which results in automatic acceleration of the Company’s obligations under such debt instruments. Any efforts to enforce payment obligations under the aforementioned debt instruments are automatically stayed as a result of the filing of the Chapter 11 Cases and the creditors’ rights of enforcement in respect of the debt instruments are subject to the applicable provisions of the Bankruptcy Code.

Item 4. Mine Safety Disclosure.

 

N/A

Item 5. Other Information.

 

None


22



Item 6. Exhibits.

The following documents are filed as a part of this report or are incorporated by reference to previous filings, if so indicated:

 

Exhibit
Number

 

Description

 

 

 

2.1

 

Articles of Incorporation and Bylaws dated November 26, 2007 as previously filed with the SEC on March 20, 2019

 

 

 

2.2

 

Articles of Merger dated, October 30, 2008 (Azure International, Inc./ Air Transport Group Holding, Inc. as previously filed with the SEC on March 20, 2019

 

 

 

2.10

 

Equity Purchase Agreement with Oscaleta Partners LLC as previously filed with the SEC on December 2, 2019

 

 

 

2.11

 

Registration Rights Agreement with Oscaleta Partners LLC as previously filed with the SEC on December 2, 2019

 

 

 

31.1

 

Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

 

 

 

31.2

 

Certification of Chief Executive Officer Pursuant to Rule 13a–14(a) or 15d-14(a) of the Securities Exchange Act of 1934**

 

 

 

32.1

 

Certification of Chief Executive Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

32.2

 

Certification of Principal Financial Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

 

 

 

*     Included in Exhibit 31.1

**   Included in Exhibit 32.1


23



SIGNATURES*

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  

Pharmagreen Biotech Inc.

 

 

 

By:

/s/  Peter Wojcik

 

 

Peter Wojcik

 

 

President and Director

Principal Executive Officer

 

 

 

 

By:

/s/  Terry Kwan

 

 

Terry Kwan

 

 

Principal Accounting Officer

 

Dated August 19, 2020


24